Payment overview · 2025
General Payments
$7,394.50
37 reported records · 10 companies
Healthcare provider profile · identity verified
Jorge Luis Perez, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI, FL · NPI 1770520074
Verified facts
What the public records show
CMS Open Payments records show Jorge Luis Perez, D.O. received $7,394.50 in general payments during 2025 across 37 reported records.
INTUITIVE SURGICAL, INC. accounted for 91.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $6,735.71 | 91.1% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $198.62 | 2.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $123.52 | 1.7% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $98.01 | 1.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.43 | 1.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.72 | 0.9% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $27.05 | 0.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.42 | 0.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.02 | 0.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.00 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $5,500.00 | 4 |
| Travel and Lodging | $1,235.71 | 4 |
| Food and Beverage | $658.79 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAVINCI XI Normalized: davinci xi |
Device | INTUITIVE SURGICAL, INC. | $5,500.00 | 4 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $1,235.71 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $198.62 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.52 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $105.50 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $98.01 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $88.43 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $88.43 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $60.96 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.06 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $27.05 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 83 |
| Alprazolam | Alprazolam | 265 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 73 |
| Famotidine | Famotidine | 234 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 198 | 54 |
| Metformin Hcl | Metformin Hcl | 195 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 49 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 157 | 48 |
| Montelukast Sodium | Montelukast Sodium | 130 | 41 |
| Lisinopril | Lisinopril | 128 | 37 |
| Gabapentin | Gabapentin | 121 | 37 |
| Omeprazole | Omeprazole | 116 | 39 |
| Lorazepam | Lorazepam | 115 | 21 |
| Losartan Potassium | Losartan Potassium | 115 | 37 |
| Dicyclomine Hcl | Dicyclomine Hcl | 112 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 18 |
| Clonazepam | Clonazepam | 102 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 34 |
| Tramadol Hcl | Tramadol Hcl | 96 | 20 |
| Azithromycin | Azithromycin | 95 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 20 |
| Eliquis | Apixaban | 87 | 14 |
| Telmisartan | Telmisartan | 87 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 27 |
| Furosemide | Furosemide | 78 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 26 |
| Meloxicam | Meloxicam | 72 | 20 |
| Carvedilol | Carvedilol | 69 | 21 |
| Simvastatin | Simvastatin | 67 | 22 |
| Azelastine Hcl | Azelastine Hcl | 66 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 28 |
| Sertraline Hcl | Sertraline Hcl | 64 | 17 |
| Temazepam | Temazepam | 64 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 24 |
| Ibuprofen | Ibuprofen | 60 | 31 |
| Januvia | Sitagliptin Phosphate | 59 | 15 |
| Prednisone | Prednisone | 59 | 26 |
| Alendronate Sodium | Alendronate Sodium | 58 | 19 |
| Jardiance | Empagliflozin | 58 | 14 |
| Ozempic | Semaglutide | 58 | 12 |
| Atenolol | Atenolol | 57 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 15 |
| Naproxen | Naproxen | 55 | 20 |
| Trazodone Hcl | Trazodone Hcl | 54 | 14 |
| Doxepin Hcl | Doxepin Hcl | 53 | 11 |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Ezetimibe | Ezetimibe | 50 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 20 |
| Meclizine Hcl | Meclizine Hcl | 48 | 25 |
| Metformin Hcl Er | Metformin Hcl | 47 | 13 |
| Spironolactone | Spironolactone | 47 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 18 |
| Benazepril Hcl | Benazepril Hcl | 43 | 11 |
| Memantine Hcl | Memantine Hcl | 43 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Irbesartan | Irbesartan | 42 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 41 | 11 |
| Synthroid | Levothyroxine Sodium | 41 | 14 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 11 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | suppressed |
| Valsartan | Valsartan | 38 | 12 |
| Ketoconazole | Ketoconazole | 36 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Allopurinol | Allopurinol | 34 | 12 |
| Ammonium Lactate | Ammonium Lactate | 33 | 12 |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Nystatin | Nystatin | 28 | 11 |
| Ciclopirox | Ciclopirox | 27 | 12 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Repaglinide | Repaglinide | 20 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Prolia | Denosumab | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,394.50 · 37 records | INTUITIVE SURGICAL, INC. | CREON, DAVINCI XI, Da Vinci Surgical System, ELIQUIS, JARDIANCE, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, Ozempic, REPATHA, Rybelsus, ZENPEP, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error